MiNK Therapeutics Inc (INKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.64+3.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
INKT — earnings miss
Dated 2026-08-13
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Why it matters: Starting this trial is key for MiNK's growth and clinical advancement. It shows progress in their pipeline.
Supportive ifA public announcement confirms the start of the ARDS Phase 2 trial.
Worry ifNo announcement about the ARDS Phase 2 trial by the end of Q3 2026.
Why it matters: Cash levels are critical for ongoing clinical trials. A significant drop could impact operations and future programs.
Worry ifCash and cash equivalents remain stable or increase from $8.8 million.
Less concerning ifCash drops below $8 million, showing financial trouble.
Why it matters: This program could make money and increase access to agenT-797. Early success may show wider international potential.
Supportive ifReports show successful patient access requests and money made from the program.
Worry ifNo patient requests or revenue reported from the program within the next quarter.
Why it matters: Getting non-dilutive funding is important for MiNK's clinical work. It impacts their finances.
Supportive ifA new grant or partnership for non-dilutive funding will be announced.
Worry ifNo updates on funding sources by the next earnings call on August 13, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$259 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $657 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,748 loss on $10,000 · 47.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Tracking cash burn will show if MiNK can keep spending in check while moving forward. This is key for staying in business.
Worry ifCash burn goes down compared to past quarters, showing good cost control.
Less concerning ifCash burn goes up a lot, raising worries about financial health.
Why it matters: Earnings results will show financial health and how well the company operates.
Watch forEarnings report shows less cash burn and better operational metrics.
Also watch forEarnings report shows more cash burn or worse operational metrics.
Why it matters: Activating U.S. sites is key for expanding the trial of agenT-797. Progress here can enhance the company's clinical footprint.
Supportive ifU.S. clinical sites are activated and begin enrolling patients for the Phase 2 trial.
Worry ifBig delays in starting U.S. sites or no new sites opened.
Why it matters: New funding can help clinical programs. It won't hurt current shareholder value.
Supportive ifNew funding over $1 million was announced for clinical programs. It won't dilute shares.
Worry ifNo new funding was announced. This raises concerns about financial health.
Why it matters: Initial results will show if agenT-797 helps patients with acute lung injury. Good results could lead to more development and investment.
Supportive ifDay 28 results show patients are alive. They have better oxygen levels and control of infections.
Worry ifResults show no big change in survival or recovery. This is compared to placebo.
Why it matters: Ongoing cash management is crucial for funding clinical trials. A drop in cash could signal financial strain.
Worry ifCash reserves stay stable or increase. This shows good capital management.
Less concerning ifCash reserves fall below $8.8 million. This raises concerns about funding.
Why it matters: Data on GVHD is key for checking MiNK's progress and market impact.
Supportive ifA press release shares positive clinical data results for GVHD.
Worry ifNegative or unclear GVHD data results were released.
Why it matters: New data could show how well agenT-797 works for treating acute lung injury. Good data could attract more interest.
Watch forGood clinical data at conferences shows that agenT-797 works well and is safe.
Also watch forBad or unclear data raises doubts about how well the therapy works.
Why it matters: Activating U.S. sites is key for expanding the trial and gathering more data. This will impact the trial's timeline.
Supportive ifAnnouncement of U.S. clinical centers activated and enrolling patients for the trial.
Worry ifNo new U.S. sites activated or delays in enrollment reported.
Why it matters: New data may show how well agenT-797 treats ongoing infections.
Watch forA presentation at ATS shows big gains for patients using agenT-797.
Also watch forA presentation at ATS shows no big gains or new info about agenT-797.
Why it matters: Initial data will show if agenT-797 helps people with severe lung injury. This could prove the therapy works in a serious area.
Supportive ifEarly data from the Phase 2 trial shows more ventilator-free days or less death.
Worry ifData shows no real improvement compared to the placebo group in the trial.